Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC
Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.
Related Articles
5 Things to Know About Lynch Syndrome
If colorectal cancer runs in your family, you might wonder whether you will be affected too. Knowing your Lynch syndrome status can provide important clues…
NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century – The Cancer Letter
Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to…
CRU Eye Symposium Wine Personality Quiz
Calling all eye care professionals looking to attend the CRU Eye Symposium this year! Are you curious about which wine matches your personality? Find out…
Olaparib Increases OS in Patients with Germline/Somatic BRCA+ Relapsed Ovarian Cancer
Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.
Relying on Progress Against Multiple Myeloma Progression
Diagnosed with multiple myeloma in 2004, Vicki Jones has lived with her cancer for more than 20 years thanks to chemotherapy and immunotherapy.
Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer
Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.
Maximizing the dual benefit of pet dogs in cancer trials
Nature Reviews Cancer – Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz and Atherton highlight comparative oncology successes,…
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented…
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
Key PointsBOVen was safe and effective for the frontline treatment of TP53-mutant MCL.The 2-year progression-free survival of 72% compares favorably with p
Membership – Society of Surgical Oncology
Join over 3,000 surgical oncologists worldwide. The Society of Surgical Oncology (SSO) is dedicated to improving multidisciplinary patient care by advancing the science, education, and…
